<DOC>
	<DOC>NCT00423527</DOC>
	<brief_summary>Multiple sclerosis is often associated with pain. There is no standard treatment of this type of pain. Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve central pain in multiple sclerosis. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis.</brief_summary>
	<brief_title>Levetiracetam in Central Pain in Multiple Sclerosis(MS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>ms diagnosis verified age &gt; 18 years central pain symptoms for more than 3 months central pain diagnosis confirmed by neurological examination adequate anticonceptive treatment for women with child bearing potential informed consent baseline pain of more than 4 on numeric rating scale other cause of pain previous allergic reaction towards levetiracetam known adverse drug reaction on levetiracetam pregnancy severe disease inability to follow study protocol treatment with antidepressants, other anticonvulsants or opioids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>central pain</keyword>
	<keyword>levetiracetam</keyword>
</DOC>